Madura J A, Wiebke E A, Howard T J, Cummings O W, Hull M T, Sherman S, Lehman G A
Department of Surgery, Indiana University Medical Center, Indianapolis, USA.
Surgery. 1997 Oct;122(4):786-92; discussion 792-3. doi: 10.1016/s0039-6060(97)90088-x.
Muncin-hypersecreting intraductal pancreatic neoplasms were first described in 1982 and have been observed in increasing numbers since. They are observed primarily by endoscopic retrograde cholangiopancreatography (ERCP) and are characterized by an intraductal papillary neoplasm that secretes thick mucin, causing pancreatic duct dilatation and obstructive pancreatitis.
Twenty patients are presented, 14 male and six female, with an average age of 59 +/- 11 years. All patients presented with abdominal pain, and most had nausea and vomiting, weight loss, and documented pancreatitis. Of the preoperative studies, ERCP was positive in all patients. Computed tomography scan, endoscopic ultrasonogram, and cytologic findings were less sensitive. Tumor markers were only positive in one patient. All 20 patients were treated surgically. Nine underwent Whipple procedure, one patient had a total pancreatectomy, and nine had distal pancreatic resections. The first patient in the series did not have a pancreatic resection, and his disease evolved into a lethal cystadenocarcinoma causing his death 99 months later.
Histopathologic findings were interpreted as borderline malignant in 17 of the 20 patients, and three patients had evidence of invasive adenocarcinoma. Two of these three patients had nodal or distant metastases at the time of diagnosis, and all three died of adenocarcinoma. Seventeen of the patients are alive and well, although two of three with positive pancreatic margins have had recurrent symptoms and have been successfully reresected.
The mucin-producing intraductal papillary tumor of the pancreas is a newly described variant of pancreatic cancer. It presents with symptoms of pancreatitis and has a progressive but more indolent course than the more lethal invasive ductal cancers. Patients with unexplained pancreatitis should undergo ERCP investigation, and aggressive surgical therapy should be carried out because the prognosis for this lesion, when appropriately treated, is more favorable than the usual pancreatic cancer.
1982年首次描述了黏液素高分泌性导管内胰腺肿瘤,此后其发现数量不断增加。主要通过内镜逆行胰胆管造影(ERCP)观察到这些肿瘤,其特征是分泌浓稠黏液的导管内乳头状肿瘤,导致胰管扩张和阻塞性胰腺炎。
报告了20例患者,其中男性14例,女性6例,平均年龄59±11岁。所有患者均有腹痛症状,大多数患者伴有恶心、呕吐、体重减轻及确诊的胰腺炎。在术前检查中,所有患者的ERCP结果均为阳性。计算机断层扫描、内镜超声检查及细胞学检查结果的敏感性较低。肿瘤标志物仅1例患者呈阳性。所有20例患者均接受了手术治疗。9例行惠普尔手术,1例患者行全胰切除术,9例行胰体尾切除术。该系列中的首例患者未接受胰腺切除术,其病情进展为致命性囊腺癌,99个月后死亡。
20例患者中,17例的组织病理学结果被判定为交界性恶性,3例有浸润性腺癌证据。这3例患者中有2例在诊断时已有淋巴结或远处转移,3例均死于腺癌。17例患者存活且状况良好,尽管3例胰腺切缘阳性的患者中有2例出现了复发症状并已成功再次切除。
胰腺黏液生成性导管内乳头状肿瘤是一种新描述的胰腺癌变异型。它表现为胰腺炎症状,与更具致命性的浸润性导管癌相比,病程呈进行性但较为惰性。不明原因胰腺炎患者应接受ERCP检查,并应积极进行手术治疗,因为该病变经适当治疗后的预后比普通胰腺癌更有利。